Surgery Partners (NASDAQ:SGRY) CEO Sells $158,060.98 in Stock

Key Points

• CEO Jason Eric Evans sold 11,462 shares at an average of $13.79 on March 6 for $158,060.98, reducing his stake by 1.7% to 662,680 shares; multiple other insiders also sold the week of Mar 5–6 and a shareholder fraud probe has been opened, creating legal and sentiment risk.
• Surgery Partners missed Q4 EPS (reported $0.12 vs. $0.31 expected) while revenue beat at $885M (+2.4% YoY), and the board authorized a $200 million buyback (up to ~9.7% of shares), signaling management believes the stock may be undervalued.
• Analyst coverage is mixed but tilted positive with nine Buys, two Holds and one Sell, a MarketBeat consensus of a "Moderate Buy" and an average price target of $24.45, while large institutions (e.g., Janus, Pentwater, UBS, Vanguard) have recently increased positions.

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) CEO Jason Eric Evans sold 11,462 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $13.79, for a total value of $158,060.98. Following the sale, the chief executive officer directly owned 662,680 shares of the company's stock, valued at $9,138,357.20. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Surgery Partners Stock Performance

SGRY traded down $0.06 during midday trading on Monday, reaching $13.30. The company had a trading volume of 1,453,571 shares, compared to its average volume of 1,733,344. The business has a 50-day moving average price of $15.16 and a two-hundred day moving average price of $18.00. Surgery Partners, Inc. has a 12-month low of $12.25 and a 12-month high of $24.60. The stock has a market cap of $1.72 billion, a PE ratio of -21.45 and a beta of 1.95. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.19). The business had revenue of $885.00 million for the quarter, compared to the consensus estimate of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.Surgery Partners's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 EPS. On average, sell-side analysts expect that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners declared that its board has authorized a stock repurchase program on Thursday, February 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 9.7% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its stock is undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC boosted its holdings in shares of Surgery Partners by 3.8% during the 4th quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company's stock valued at $209,162,000 after acquiring an additional 501,401 shares during the last quarter. Pentwater Capital Management LP grew its position in Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company's stock valued at $252,777,000 after buying an additional 4,681,000 shares during the period. UBS Group AG boosted its stake in shares of Surgery Partners by 111.4% during the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company's stock worth $120,571,000 after acquiring an additional 4,113,052 shares during the last quarter. Vanguard Group Inc. lifted its position in Surgery Partners by 5.9% during the third quarter. Vanguard Group Inc. now owns 7,614,514 shares of the company's stock valued at $164,778,000 after purchasing an additional 424,518 shares in the last quarter. Finally, King Street Capital Management L.P. raised its stake in shares of Surgery Partners by 24.5% in the second quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company's stock worth $138,382,000 after buying an additional 1,225,000 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SGRY shares. Mizuho lowered their price target on Surgery Partners from $19.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Surgery Partners in a research report on Wednesday, March 4th. Benchmark reaffirmed a "buy" rating on shares of Surgery Partners in a research note on Tuesday, March 3rd. TD Cowen dropped their price target on Surgery Partners from $28.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Surgery Partners in a report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $24.45.

Trending Headlines about Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.